Linagliptin
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding.
| Catalog Number | API668270120 |
| Alternative Name(s) | Tradjenta;Ondero;BI-1356 |
| Research Area | Hypoglycemic APIs |
| Molecular Formula | C25H28N8O2 |
| CAS# | 668270-12-0 |
| SMILES | CC#CCN1C2=C(N=C1N3CCCC(C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C |
| Size | inquiry |
| Supplier Page | https://www.protheragen-ing.com/linagliptin-item-12542.html |